Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | ACHE | P22303 | 12/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.42 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.42 |
| ▸ | NAAA | Q02083 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29939 | 0.83 | ACHE (0.58) | FAAHACHEEPHX1 | |
| SCHEMBL20839538 | 0.81 | ACHE (0.61) | FAAHTSHRACHEEPHX1 | |
| SCHEMBL11338236 | 0.81 | ACHE (0.61) | FAAHTSHRACHEEPHX1 | |
| SCHEMBL9866335 | 0.80 | EGLN1 (0.55) | FAAHTSHR | |
| SCHEMBL1486852 | 0.77 | ACHE (0.55) | FAAHTSHRACHEHPGDEPHX1 | |
| SCHEMBL29835 | 0.76 | FAAH (0.46) | FAAHTSHRACHEHPGDEPHX1 | |
| SCHEMBL10889007 | 0.75 | TSHR (0.49) | FAAHTSHRACHEHPGDEPHX1 | |
| SCHEMBL6449183 | 0.75 | TSHR (0.58) | FAAHTSHRHPGDEPHX1NAAA | |
| SCHEMBL8390789 | 0.75 | FAAH (0.49) | FAAHTSHRACHEEPHX1NAAA | |
| SCHEMBL1723694 | 0.74 | MAPT (0.42) | FAAHTSHRHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050096331-A1 | Novel compounds and their use in medicine process for their preparation and pharmaceutical compositions containing them | DR. REDDY'S LABORATORIES INC. | 2005-05-05 | — | — | US | claimed |
| US-20020077320-A1 | Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them | DR. REDDY'S RESEARCH FOUNDATION AND REDDY- CHEMINOR, INC. | 2002-06-20 | — | — | US | claimed |
| US-6043255-A | ADMINISTERING TO A PATIENT SUFFERING FROM COGNITIVE DISORDER IN NEURODEGENERATIVE DISEASES A 1,4-DI-SUBSTITUTED PIPERIDINE COMPOUND | SCHERING CORPORATION (US) | 2000-03-28 | — | — | US | claimed |
| US-5641795-A | COMPOUNDS (TASTANDS, E.G. A DIPEPTIDE CONTAINING TAURINE AND/OR ALANINE) USED TO REDUCE OR ELIMINATE A BITTER OR METALLIC TASTE; FOODS; DRUGS; ARTIFICIAL SWEETENERS; POTASSIUM CHLORIDE | BIORESEARCH INC. (US) | 1997-06-24 | — | — | US | claimed |
| US-6906081-B2 | Use of dual H3/M2 antagonists in the treatment of cognition deficit disorders | SCHERING CORPORATION (US) | 2005-06-14 | — | — | US | disclosed |
| US-20050096331-A1 | Novel compounds and their use in medicine process for their preparation and pharmaceutical compositions containing them | DR. REDDY'S LABORATORIES INC. | 2005-05-05 | — | — | US | disclosed |
| EP-1408965-A2 | USE OF DUAL H3/M2 ANTAGONISTS WITH A BIPIPERIDINIC STRUCTURE IN THE TREATMENT OF COGNITION DEFICIT DISORDERS | SCHERING CORPORATION (US) | 2004-04-21 | — | — | EP | disclosed |
| US-6608194-B1 | Hypolipidemic, antihyperglycemic, antiobesity and hypocholes-terolemic agents | DR. REDDY'S LABORATORIES LIMITED (IN) | 2003-08-19 | — | — | US | disclosed |
| US-20020151565-A1 | Use of dual H3/M2 antagonists in the treatment of cognition deficit disorders | SCHERING CORPORATION | 2002-10-17 | — | — | US | disclosed |
| WO-2002072093-A2 | USE OF DUAL H3/M2 ANTAGONISTS WITH A BIPIPERIDINIC STRUCTURE IN THE TREATMENT OF COGNITION DEFICIT DISORDERS | SCHERING CORPORATION (US) | 2002-09-19 | — | — | WO | disclosed |
| US-6043255-A | ADMINISTERING TO A PATIENT SUFFERING FROM COGNITIVE DISORDER IN NEURODEGENERATIVE DISEASES A 1,4-DI-SUBSTITUTED PIPERIDINE COMPOUND | SCHERING CORPORATION (US) | 2000-03-28 | — | — | US | disclosed |
| US-5889006-A | Muscarinic antagonists | SCHERING CORPORATION (US) | 1999-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020077320-A1 | Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them | LIPC, GPR119, CPT1A | FAAH 435/4885TSHR 2506/4885ACHE 2649/4885 |
| US-20050096331-A1 | Novel compounds and their use in medicine process for their preparation and pharmaceutical compositions containing them | GPR119, LIPA, CETP | FAAH 1536/4885TSHR 2921/4885ACHE 3412/4885 |
| US-20020151565-A1 | Use of dual H3/M2 antagonists in the treatment of cognition deficit disorders | HRH3, CHRM2, HRH4 | FAAH 210/4885TSHR 259/4885ACHE 158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.